WINTON GROUP Ltd Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

WINTON GROUP Ltd grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 1,093.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,248 shares of the company's stock after purchasing an additional 3,892 shares during the period. WINTON GROUP Ltd's holdings in Eli Lilly and Company were worth $3,279,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership grew its position in Eli Lilly and Company by 1.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 41,618 shares of the company's stock valued at $32,129,000 after acquiring an additional 574 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Eli Lilly and Company by 11.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,303,992 shares of the company's stock worth $1,019,696,000 after purchasing an additional 137,287 shares in the last quarter. Cottage Street Advisors LLC lifted its stake in Eli Lilly and Company by 7.0% in the 4th quarter. Cottage Street Advisors LLC now owns 520 shares of the company's stock valued at $402,000 after purchasing an additional 34 shares during the last quarter. Tyler Stone Wealth Management boosted its position in Eli Lilly and Company by 39.0% in the fourth quarter. Tyler Stone Wealth Management now owns 1,564 shares of the company's stock valued at $1,207,000 after buying an additional 439 shares in the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,601,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have recently commented on LLY shares. Bank of America reiterated a "buy" rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research note on Thursday, March 6th. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,009.72.

Eli Lilly and Company Stock Up 0.4 %

Shares of Eli Lilly and Company stock traded up $2.91 during trading on Monday, reaching $825.42. 3,736,491 shares of the company traded hands, compared to its average volume of 3,311,204. The firm has a market capitalization of $782.64 billion, a PE ratio of 70.49, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a 50 day moving average price of $846.30 and a 200-day moving average price of $835.00. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a stock repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.